UNSPSC 51451606: Triclabendazole

This classification denotes an antihelminthic agent with the molecular formula C14H9Cl3N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4784C8E03O, chemically known as 6-chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole but generally known as triclabendazole, which bears US NIH Compound Identifier 50248. European Medicines Agency schedules Triclabendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11267MIG.

UNSPSC 51451606 Triclabendazole is a Commodity code that does not reflect the actual work being solicited under it in recent state and local procurement activity. The four opportunities posted between January and June 2026 involve naloxone and drug deactivation systems, direct-to-manufacturer pharmacy prescriptions, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products — none of which relate to triclabendazole, an antiparasitic veterinary or human pharmaceutical. The code shows little relevant recent activity aligned to its nominal scope.

The mismatch between the code's stated commodity and the opportunities tagged to it suggests either a systematic cataloging error in the issuing bodies' taxonomies or a database indexing problem. Firms evaluating this code should verify directly with state and local procurement offices whether opportunities labeled as 51451606 actually involve triclabendazole acquisition or whether the code assignment is incidental to broader pharmaceutical, medical supply, or health-services procurement. The recent opportunities span Seminole County, Florida (IFB for naloxone and drug deactivation systems, due July 26, 2023); Texas Health and Human Services Commission (RFI for direct-to-manufacturer prescriptions, due April 3, 2026); City of Tampa Fire Department (IFB for medical and first aid supplies, due March 13, 2026, with an estimated contract value of $700,000); and the Minnesota Multistate Cooperative Purchasing Alliance (RFP for generic pharmaceuticals and OTC products, due March 26, 2026). Unless the code is explicitly tied to triclabendazole-specific opportunities in future solicitations, business development professionals should treat this code as inactive for procurement planning purposes and monitor issuing bodies' actual pharmaceutical and medical-supply RFPs under their broader procurement portals.